| ［1］ |
中国研究型医院学会皮肤科学专业委员会, 中国医师协会皮肤科医师分会. 慢性光化性皮炎诊疗专家共识（2023版）［J］. 中华皮肤科杂志, 2023,56（12）:1096⁃1106. doi: 10.35541/cjd. 20230433.
|
| ［2］ |
Ko DY, Choi SH, Ha SM, et al. The clinical severity score of chronic actinic dermatitis correlates with in vivo photoallergic reactions and the immunologic parameters related to a shift towards Th2 immunity from the Th2/Th1 balanced status in patients with chronic actinic dermatitis［J］. Photodermatol Photoimmunol Photomed, 2016,32（4）:199⁃206. doi: 10.1111/phpp.12244.
|
| ［3］ |
Beck LA, Cork MJ, Amagai M, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis［J］. JID Innov, 2022,2（5）:100131. doi: 10.1016/j.xjidi.2022.100131.
|
| ［4］ |
Wohlrab J, Stintzing D, Schultz L, et al. Influence of Janus kinase inhibitors on the neuronal activity as a proof⁃of⁃concept model for itch［J］. Skin Pharmacol Physiol, 2022,35（2）:94⁃101. doi: 10. 1159/000519669.
|
| ［5］ |
Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomised, double⁃blind, multicentre phase 3 trial［J］. Lancet, 2022,400（10348）:273⁃282. doi: 10.1016/S0140⁃6736（22）01199⁃0.
|
| ［6］ |
Ständer S, Kwatra SG, Silverberg JI, et al. Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate⁃to⁃severe atopic dermatitis: subgroup analysis of the randomized phase Ⅲ JADE COMPARE Trial［J］. Am J Clin Dermatol, 2023,24（1）:97⁃107. doi: 10.1007/s40257⁃022⁃00738⁃4.
|
